Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FENC Adherex Technologies	$7.84 -4.2%	$8.33	$3.96 ▼ $9.30	$226.86M	0.4	51,129 shs	54,838 shs
MLYS Mineralys Therapeutics	$13.66 -3.5%	$14.52	$8.24 ▼ $18.38	$922.23M	-0.29	637,447 shs	1.11 million shs
PROK ProKidney	$2.82 +1.8%	$1.78	$0.46 ▼ $7.13	$810.77M	1.26	38.09 million shs	1.32 million shs
REPL Replimune Group	$7.60 +8.1%	$9.00	$2.68 ▼ $17.00	$546.98M	0.67	21.71 million shs	9.72 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FENC Adherex Technologies	-4.16%	-9.15%	-8.20%	+24.44%	+21.17%
MLYS Mineralys Therapeutics	-3.46%	-4.61%	-4.48%	-11.41%	+10.25%
PROK ProKidney	+1.81%	-14.29%	+387.30%	+257.32%	+20.51%
REPL Replimune Group	+8.11%	+141.27%	-20.42%	-24.08%	-24.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FENC Adherex Technologies	1.8011 of 5 stars	3.6	1.0	0.0	0.6	3.3	0.0
MLYS Mineralys Therapeutics	2.54 of 5 stars	3.4	1.0	0.0	3.1	4.2	0.0
PROK ProKidney	3.2547 of 5 stars	3.2	4.0	0.0	2.9	3.3	0.6
REPL Replimune Group	3.8716 of 5 stars	2.2	4.0	4.5	2.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FENC Adherex Technologies	3.25	Buy	$13.00	65.82% Upside
MLYS Mineralys Therapeutics	2.75	Moderate Buy	$32.25	136.09% Upside
PROK ProKidney	2.40	Hold	$6.25	121.63% Upside
REPL Replimune Group	2.33	Hold	$7.67	0.88% Upside

Current Analyst Ratings Breakdown

Latest FENC, REPL, MLYS, and PROK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
7/23/2025	REPL Replimune Group	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$17.00 ➝ $3.00
7/23/2025	REPL Replimune Group	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Underperform	$27.00 ➝ $2.00
7/23/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/22/2025	REPL Replimune Group	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/22/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/22/2025	REPL Replimune Group	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$31.00 ➝ $6.00
7/22/2025	REPL Replimune Group	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$21.00 ➝ $3.00
7/22/2025	REPL Replimune Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$19.00 ➝ $9.00
7/22/2025	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$3.00
7/15/2025	PROK ProKidney	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $8.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FENC Adherex Technologies	$47.54M	4.57	$0.03 per share	253.28	($0.21) per share	-37.33
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
PROK ProKidney	$306K	2,697.41	N/A	N/A	($3.41) per share	-0.83
REPL Replimune Group	N/A	N/A	N/A	N/A	$5.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FENC Adherex Technologies	-$440K	-$0.51	N/A	N/A	N/A	-45.52%	N/A	-26.37%	8/12/2025 (Estimated)
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-71.15%	-65.71%	8/12/2025 (Estimated)
PROK ProKidney	-$61.19M	-$0.60	N/A	N/A	N/A	N/A	N/A	-15.03%	8/8/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.07	N/A	N/A	N/A	N/A	-57.98%	-45.21%	8/14/2025 (Estimated)

Latest FENC, REPL, MLYS, and PROK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q1 2026	REPL Replimune Group	-$0.85	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	FENC Adherex Technologies	-$0.06	N/A	N/A	N/A	$9.52 million	N/A
8/12/2025	Q2 2025	MLYS Mineralys Therapeutics	-$0.78	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	PROK ProKidney	-$0.14	N/A	N/A	N/A	N/A	N/A
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/13/2025	Q1 2025	FENC Adherex Technologies	-$0.12	-$0.04	+$0.08	-$0.04	$8.18 million	$8.51 million
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	-$0.79	+$0.23	-$0.79	N/A	N/A
5/12/2025	Q1 2025	PROK ProKidney	-$0.16	-$0.13	+$0.03	-$0.13	N/A	$0.23 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FENC Adherex Technologies	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FENC Adherex Technologies	N/A	5.13	4.97
MLYS Mineralys Therapeutics	N/A	26.48	26.48
PROK ProKidney	N/A	10.96	10.96
REPL Replimune Group	0.17	7.95	7.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FENC Adherex Technologies	55.51%
MLYS Mineralys Therapeutics	84.46%
PROK ProKidney	51.59%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
FENC Adherex Technologies	11.76%
MLYS Mineralys Therapeutics	25.56%
PROK ProKidney	41.49%
REPL Replimune Group	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FENC Adherex Technologies	10	27.73 million	24.47 million	Optionable
MLYS Mineralys Therapeutics	28	65.18 million	48.52 million	Optionable
PROK ProKidney	3	292.70 million	171.26 million	Optionable
REPL Replimune Group	210	77.81 million	70.96 million	Optionable

FENC, REPL, MLYS, and PROK Headlines

Recent News About These Companies

ROSEN, NATIONAL TRIAL ATTORNEYS, Encourages Replimune Group, Inc. ...

5 hours ago | gurufocus.com

ROSEN, NATIONAL TRIAL ATTORNEYS, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL

August 1 at 9:48 PM | globenewswire.com

Replimune Group (NASDAQ:REPL) Shares Gap Down - Here's What Happened

August 1 at 1:11 PM | marketbeat.com

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

August 1 at 11:03 AM | globenewswire.com

Lost Money on Replimune Group, Inc.(REPL)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

August 1 at 9:00 AM | prnewswire.com

REPL LAWSUIT ALERT: Levi & Korsinsky Notifies Replimune Group, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

July 31 at 6:51 PM | theglobeandmail.com

Best Small Cap Stocks To Keep An Eye On - July 30th

July 31 at 5:35 PM | marketbeat.com

Investors in Replimune Group, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights – REPL

July 31 at 4:11 PM | globenewswire.com

REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

July 31 at 4:00 PM | globenewswire.com

Replimune Group (NASDAQ:REPL) Upgraded to "Overweight" at Cantor Fitzgerald

July 31 at 3:05 PM | marketbeat.com

Biotech Stocks To Follow Today - July 30th

July 31 at 2:29 PM | marketbeat.com

Replimune Group (NASDAQ:REPL) Shares Gap Up - Time to Buy?

July 31 at 12:23 PM | marketbeat.com

Stock Traders Purchase High Volume of Replimune Group Call Options (NASDAQ:REPL)

July 31 at 10:59 AM | marketbeat.com

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 31 at 10:54 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

July 31 at 10:00 AM | prnewswire.com

The Gross Law Firm Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - REPL

July 31 at 8:45 AM | prnewswire.com

Replimune Group Inc. Stock Grades | REPL | Barron's

July 31 at 4:52 AM | barrons.com

Replimune Group Inc. (REPL) Stock Price Today - WSJ

July 31 at 4:52 AM | wsj.com

Cantor Fitzgerald Upgrades Replimune Group (REPL)

July 31 at 4:52 AM | msn.com

Replimune Stock Catches Retail Fire As Analyst Says FDA Shakeup Removes 'Major Obstacle' For Skin Cancer Drug's Potential Approval

July 30 at 11:52 PM | msn.com

Replimune surges as Cantor upgrades on possible FDA U-turn on lead drug

July 30 at 6:50 PM | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FENC, REPL, MLYS, and PROK Company Descriptions

Adherex Technologies NASDAQ:FENC

$7.84 -0.34 (-4.16%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$7.86 +0.02 (+0.26%)

As of 08/1/2025 04:34 PM Eastern

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Mineralys Therapeutics NASDAQ:MLYS

$13.66 -0.49 (-3.46%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$13.67 +0.01 (+0.07%)

As of 08/1/2025 06:53 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

ProKidney NASDAQ:PROK

$2.82 +0.05 (+1.81%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.82 +0.01 (+0.18%)

As of 08/1/2025 07:58 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Replimune Group NASDAQ:REPL

$7.60 +0.57 (+8.11%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$7.71 +0.11 (+1.50%)

As of 08/1/2025 07:59 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time